Abstract
Background: Dobutamine stress echocardiography (DSE) is a common, useful test for the evaluation of coronary artery disease. Two of 650 patients who underwent DSE at our institution sustained nonfatal myocardial infarction either during DSE or shortly thereafter. Although DSE is associated with low morbidity rates, this rate is higher than our experience with exercise treadmill testing (ETT). Methods: Six individuals who did not undergo DSE or ETT were enrolled to evaluate direct in vitro effects of dobutamine on platelets. Nine patients undergoing DSE and seven patients undergoing ETT were enrolled to evaluate in vive platelet activation. We used flow cytometry and fluorescent-labeled monoclonal antibodies to activation-dependent platelet antigens to detect dobutamine-associated platelet activation both in vitro and in vivo. Results: In vitro we found a synergistic increase in epinephrine-induced CD62 expression in the presence of dobutamine. The response to the combination of dobutamine and epinephrine was 151% to 565% of the expected response. In vivo there was a dose- and time-dependent rise in the percentage of platelets expressing CD62 in all nine subjects undergoing DSE. The median percentage of platelets expressing CD62 was 1.6% (range 0.1% to 6.8%), 6.5% (range 0.2% to 11.7%), 11.6% (range 5.9% to 19.1%), and 11.4% (range 7.2% to 25.0%) in the samples obtained at baseline, 20 μg/kg/min of dobutamine, 40 μg/kg/min of dobutamine, and during the recovery phase, respectively (repeated measures analysis of variance, p = 0.02). There was no increase in CD62 expression on platelets obtained from seven patients at peak ETT. The median percentage of CD62 at baseline ETT was 1.9% (range 0.2% to 7.3%) and at peak was 2.6% (range 0.4% to 7.0%) (p = 0.156, Wilcoxon signed rank test). Conclusion: We conclude that platelet activation occurs in vive in patients undergoing DSE and that this may be caused by a synergistic effect of dobutamine with physiologic platelet agonists.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 888-900 |
| Number of pages | 13 |
| Journal | American Heart Journal |
| Volume | 135 |
| Issue number | 5 I |
| DOIs | |
| State | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Platelet activation during dobutamine stress echocardiography. / Galloway, M. T.; Paglieroni, T. G.; Wun, Theodore; Arena, F. J.; Lewis, W. R.
In: American Heart Journal, Vol. 135, No. 5 I, 1998, p. 888-900.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Platelet activation during dobutamine stress echocardiography
AU - Galloway, M. T.
AU - Paglieroni, T. G.
AU - Wun, Theodore
AU - Arena, F. J.
AU - Lewis, W. R.
PY - 1998
Y1 - 1998
N2 - Background: Dobutamine stress echocardiography (DSE) is a common, useful test for the evaluation of coronary artery disease. Two of 650 patients who underwent DSE at our institution sustained nonfatal myocardial infarction either during DSE or shortly thereafter. Although DSE is associated with low morbidity rates, this rate is higher than our experience with exercise treadmill testing (ETT). Methods: Six individuals who did not undergo DSE or ETT were enrolled to evaluate direct in vitro effects of dobutamine on platelets. Nine patients undergoing DSE and seven patients undergoing ETT were enrolled to evaluate in vive platelet activation. We used flow cytometry and fluorescent-labeled monoclonal antibodies to activation-dependent platelet antigens to detect dobutamine-associated platelet activation both in vitro and in vivo. Results: In vitro we found a synergistic increase in epinephrine-induced CD62 expression in the presence of dobutamine. The response to the combination of dobutamine and epinephrine was 151% to 565% of the expected response. In vivo there was a dose- and time-dependent rise in the percentage of platelets expressing CD62 in all nine subjects undergoing DSE. The median percentage of platelets expressing CD62 was 1.6% (range 0.1% to 6.8%), 6.5% (range 0.2% to 11.7%), 11.6% (range 5.9% to 19.1%), and 11.4% (range 7.2% to 25.0%) in the samples obtained at baseline, 20 μg/kg/min of dobutamine, 40 μg/kg/min of dobutamine, and during the recovery phase, respectively (repeated measures analysis of variance, p = 0.02). There was no increase in CD62 expression on platelets obtained from seven patients at peak ETT. The median percentage of CD62 at baseline ETT was 1.9% (range 0.2% to 7.3%) and at peak was 2.6% (range 0.4% to 7.0%) (p = 0.156, Wilcoxon signed rank test). Conclusion: We conclude that platelet activation occurs in vive in patients undergoing DSE and that this may be caused by a synergistic effect of dobutamine with physiologic platelet agonists.
AB - Background: Dobutamine stress echocardiography (DSE) is a common, useful test for the evaluation of coronary artery disease. Two of 650 patients who underwent DSE at our institution sustained nonfatal myocardial infarction either during DSE or shortly thereafter. Although DSE is associated with low morbidity rates, this rate is higher than our experience with exercise treadmill testing (ETT). Methods: Six individuals who did not undergo DSE or ETT were enrolled to evaluate direct in vitro effects of dobutamine on platelets. Nine patients undergoing DSE and seven patients undergoing ETT were enrolled to evaluate in vive platelet activation. We used flow cytometry and fluorescent-labeled monoclonal antibodies to activation-dependent platelet antigens to detect dobutamine-associated platelet activation both in vitro and in vivo. Results: In vitro we found a synergistic increase in epinephrine-induced CD62 expression in the presence of dobutamine. The response to the combination of dobutamine and epinephrine was 151% to 565% of the expected response. In vivo there was a dose- and time-dependent rise in the percentage of platelets expressing CD62 in all nine subjects undergoing DSE. The median percentage of platelets expressing CD62 was 1.6% (range 0.1% to 6.8%), 6.5% (range 0.2% to 11.7%), 11.6% (range 5.9% to 19.1%), and 11.4% (range 7.2% to 25.0%) in the samples obtained at baseline, 20 μg/kg/min of dobutamine, 40 μg/kg/min of dobutamine, and during the recovery phase, respectively (repeated measures analysis of variance, p = 0.02). There was no increase in CD62 expression on platelets obtained from seven patients at peak ETT. The median percentage of CD62 at baseline ETT was 1.9% (range 0.2% to 7.3%) and at peak was 2.6% (range 0.4% to 7.0%) (p = 0.156, Wilcoxon signed rank test). Conclusion: We conclude that platelet activation occurs in vive in patients undergoing DSE and that this may be caused by a synergistic effect of dobutamine with physiologic platelet agonists.
UR - http://www.scopus.com/inward/record.url?scp=0031809005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031809005&partnerID=8YFLogxK
U2 - 10.1016/S0002-8703(98)70051-1
DO - 10.1016/S0002-8703(98)70051-1
M3 - Article
VL - 135
SP - 888
EP - 900
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 5 I
ER -